Novogen Ltd is seeking shareholder approval to change its name to Kazia Therapeutics Ltd. and to consolidate its shares.
Novogen intends to implement a 1-for-10 share consolidation to have a more appropriate capital structure as well as reduce administrative costs resulting from a large number of issued shares.
The share consolidation is expected to be effective Dec. 31.